Pharmaceutical Technology
If approved, Perfuse’s PER-001 could continue Bayer’s ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea.
Pharmaceutical Technology
If approved, Perfuse's PER-001 could continue Bayer's ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea.
Pharmaceutical Technology
If approved, Perfuse’s PER-001 could continue Bayer’s ophthalmology legacy defined by blockbuster retinal disease therapy, Eylea.